Bronchogen is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Bronchogen (Tetrapeptide Ala-Glu-Asp-Leu (AEDL)) is researched primarily for respiratory epithelial repair, reduced mucus hypersecretion, inflammation reduction, improved ciliary function, enhanced mucosal immunity. One of the few peptides with direct gene expression modulation in lung tissue, with preclinical data showing complete reversal of COPD-like remodeling after just one month. It belongs to the Peptide bioregulator category of compounds.
What Is Bronchogen?
Bronchogen (Tetrapeptide Ala-Glu-Asp-Leu (AEDL)) is a Peptide bioregulator. Synthetic tetrapeptide derived from lung tissue extracts, designed to modulate bronchial epithelial cell function.
One of the few peptides with direct gene expression modulation in lung tissue, with preclinical data showing complete reversal of COPD-like remodeling after just one month. It has attracted significant research interest for its potential effects on respiratory epithelial repair, reduced mucus hypersecretion, inflammation reduction, improved ciliary function, enhanced mucosal immunity.
How Does Bronchogen Produce These Benefits?
Operates through gene expression modulation — interacts with DNA regulatory sequences and histone proteins in lung cells to reduce pro-inflammatory cytokines, promote regeneration of bronchial epithelium, and restore ciliated cell populations. Also enhances local mucosal immunity by increasing secretory IgA.
This multi-pathway activity is why Bronchogen shows potential across several different applications rather than being limited to a single use case.
Can Bronchogen Help With Respiratory Epithelial Repair?
Research suggests Bronchogen may support respiratory epithelial repair through its peptide bioregulator activity. One-month administration in COPD animal models eliminated bronchial remodeling symptoms including goblet cell hyperplasia, squamous metaplasia, and lymphocytic infiltration. Increased secretory IgA and surfactant protein B levels. Research remains preclinical.
Protocols targeting respiratory epithelial repair typically use 200 mcg daily administered once daily for 28-30 days.
Can Bronchogen Help With Reduced Mucus Hypersecretion?
Research suggests Bronchogen may support reduced mucus hypersecretion through its peptide bioregulator activity. One-month administration in COPD animal models eliminated bronchial remodeling symptoms including goblet cell hyperplasia, squamous metaplasia, and lymphocytic infiltration. Increased secretory IgA and surfactant protein B levels. Research remains preclinical.
Protocols targeting reduced mucus hypersecretion typically use 200 mcg daily administered once daily for 28-30 days.
Can Bronchogen Help With Inflammation Reduction?
Research suggests Bronchogen may support inflammation reduction through its peptide bioregulator activity. One-month administration in COPD animal models eliminated bronchial remodeling symptoms including goblet cell hyperplasia, squamous metaplasia, and lymphocytic infiltration. Increased secretory IgA and surfactant protein B levels. Research remains preclinical.
Protocols targeting inflammation reduction typically use 200 mcg daily administered once daily for 28-30 days.
Can Bronchogen Help With Improved Ciliary Function?
Research suggests Bronchogen may support improved ciliary function through its peptide bioregulator activity. One-month administration in COPD animal models eliminated bronchial remodeling symptoms including goblet cell hyperplasia, squamous metaplasia, and lymphocytic infiltration. Increased secretory IgA and surfactant protein B levels. Research remains preclinical.
Protocols targeting improved ciliary function typically use 200 mcg daily administered once daily for 28-30 days.
Can Bronchogen Help With Enhanced Mucosal Immunity?
Research suggests Bronchogen may support enhanced mucosal immunity through its peptide bioregulator activity. One-month administration in COPD animal models eliminated bronchial remodeling symptoms including goblet cell hyperplasia, squamous metaplasia, and lymphocytic infiltration. Increased secretory IgA and surfactant protein B levels. Research remains preclinical.
Protocols targeting enhanced mucosal immunity typically use 200 mcg daily administered once daily for 28-30 days.
Can Stacking Enhance Bronchogen Benefits?
Complements respiratory support protocols with LL-37 (antimicrobial) and VIP (bronchodilation) for comprehensive lung health.
See our Bronchogen stacking guide for detailed combination protocols.
What Is the Bottom Line on Bronchogen Benefits?
Bronchogen is researched for respiratory epithelial repair, reduced mucus hypersecretion, inflammation reduction, improved ciliary function, enhanced mucosal immunity. The evidence base includes: One-month administration in COPD animal models eliminated bronchial remodeling symptoms including goblet cell hyperplasia, squamous metaplasia, and lymphocytic infiltration. Increased secretory IgA and surfactant protein B levels. Research remains preclinical.
Bronchogen is not fda-approved. research compound only. available as investigational peptide in some european countries. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
Bronchogen : Benefits, Dosage, Side Effects & Research
Related Reading
- Bronchogen Dosage Guide
- Bronchogen Side Effects
- Bronchogen Stacking Guide
- Bronchogen Cycle Guide
- Bronchogen Research
- LL-37 Complete Guide
Calculate Your Bronchogen Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Bronchogen.
Open Calculator →Research-Grade Sourcing
If you're going to research Bronchogen, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Bronchogen?
Bronchogen (Tetrapeptide Ala-Glu-Asp-Leu (AEDL)) is a Peptide bioregulator. Synthetic tetrapeptide derived from lung tissue extracts, designed to modulate bronchial epithelial cell function. It is researched for respiratory epithelial repair, reduced mucus hypersecretion, inflammation reduction, improved ciliary function, enhanced mucosal immunity.
What is the recommended Bronchogen dosage?
Common dosages: 200 mcg daily administered once daily via subcutaneous injection. Cycle length: 28-30 days. Half-life: not established. Use our peptide calculator for exact reconstitution math.
What are the side effects of Bronchogen?
No reported adverse effects in animal models. Human safety data unavailable. Generally well-tolerated with no systemic toxicity observed in preclinical studies.
Is Bronchogen safe?
Bronchogen has shown a favorable safety profile in research. Not FDA-approved. Research compound only. Available as investigational peptide in some European countries. All research should follow appropriate safety protocols.